This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Phosphodiesterase (PDE5) inhibitors in erectile dysfunction

Authoring team

In the UK the currently available phosphodiesterase (PDE5) inhibitors are sildenafil Viagra), tadalafil (Cialis) and vardenafil (Levitra)

mechanism of action:

  • PDE5 inhibitors prevent the degradation of cyclic GMP thereby prolonging production of the vasodilator nitric oxide. PDE5 inhibitors are only effective in the context of sexual arousal

dosing of PDE5 inhibitors:

  • doses may need to be titrated to achieve effect
    • the majority of diabetics need the maximum dose of PDE5 inhibitor to achieve effect (1)
    • PDE5 inhibitors may take several doses over time to work. The patient should be warned that he may need 8 attempts before a satisfactory erection occurs – at least 4 at the highest dose (1)

Adverse effects:

  • these occur secondary to smooth muscle relaxation and include headache, flushing and acid reflux but are not usually limiting
  • transient blue vision can occur with use of sildenafil

The respective summary of products must be consulted before prescribing any of the drugs mentioned.

Reference:

  1. British Heart Foundation (factfile 6/2005).Drugs and Erectile Dysfunction.
  2. Prescriber (2003), 14 (20), 28-31.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.